Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients

This was a multicenter clinical trial of rituximab, a chimeric monoclonal IgG antibody directed against CD20, for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. In total, 20 patients were treated with two doses of rituximab (1000 mg; 2 weeks apart) on days 0 and 14. The prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamagami, Jun, Kurihara, Yuichi, Funakoshi, Takeru, Saito, Yasuko, Tanaka, Ryo, Takahashi, Hayato, Ujiie, Hideyuki, Iwata, Hiroaki, Hirai, Yoji, Iwatsuki, Keiji, Ishii, Norito, Sakurai, Jun, Abe, Takayuki, Takemura, Ryo, Mashino, Naomi, Abe, Masahiro, Amagai, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091989/
https://www.ncbi.nlm.nih.gov/pubmed/36196051
http://dx.doi.org/10.1111/1346-8138.16597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091989/
https://www.ncbi.nlm.nih.gov/pubmed/36196051
http://dx.doi.org/10.1111/1346-8138.16597

Ejemplares similares